Neoadjuvant PD-1 blockade in dMMR tumors "could potentially eradicate the need for chemotherapy, radiation, and surgery in ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...